QWINT-3 evaluated the efficacy and safety of once-weekly efsitora compared to once-daily insulin degludec for 78 weeks in adults with type 2 diabetes currently treated with basal insulin.

The approval covers all 27 European Union member states. Tresiba (insulin degludec) is a once-daily new-generation based insulin analogue with an ultra-long duration of action. Ryzodeg (insulin ...

The company says it took part in the tender process and secured places for each of its insulin products aside from Ryzodeg (insulin degludec/insulin aspart) and Xultophy (insulin degludec ...

Both studies met their primary endpoint by demonstrating that efsitora’s HbA1C reduction was non-inferior to that of insulin glargine and insulin degludec, respectively. Diabetes is a high ...